Immunotherapy has changed the way physicians treat cancer patients. This approach to therapy targets the immune system to redirect cells toward the tumor. | Immunology ...

Gut bacteria are to blame for the failure of immune checkpoint therapy for ovarian cancer, new UVA Cancer Center research ...

University of Virginia Cancer Center researchers have explained the failure of immune checkpoint therapy for ovarian cancer ...

Ovarian tumors, often detected incidentally, pose a diagnostic challenge that requires careful management. Decisions depend on assessing the malignancy risk and addressing patient symptoms. For benign ...

The high prevalence of sarcopenia in patients with ovarian and endometrial cancers underscores the importance of early ...

The guideline authors used data from 61 studies to provide recommendations on the use of neoadjuvant chemotherapy in patients with newly diagnosed, stage III-IV epithelial ovarian, fallopian tube, or ...

High heat shock protein 60 (HSP60) expression in patients with ovarian cancer is associated with larger tumors, advanced stages, and worse survival outcomes, highlighting its potential as a ...

JSKN003 is an anti-HER2 biparatopic ADC, which is developed inhouse with Alphamab's proprietary Glycan-specific conjugation platform. Compared with its ADC counterparts, JSKN003 demonstrated better ...

OnCusp Therapeutics, Inc., a clinical stage biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients, today ...

Fibroblast growth factor receptors (FGFRs) are critical drivers of oncogenesis in various solid tumors, including urothelial carcinoma, hepatocellular carcinoma, ovarian cancer and lung adenocarcinoma ...